Monday, August 7, 2023 Daily Archives

Oramed and Hefei Tianhui form $60m oral insulin JV

by

Oramed Pharma, a New York-Israel biopharma, signed a non-binding term sheet with Hefei Tianhui Biotech (HTBT) forming a joint venture to commercialize Oramed’s oral drug delivery products. HTBT will invest $60 million in the JV, while Oramed will add $10 million, with each company owning 50%. The focus of the new venture will be the global commercialization of innovative products based on Oramed’s oral insulin and POD (Protein Oral Delivery) pipeline. HTBT will contribute its manufacturing capacity and experience. The…

August 7, 2023

Sartorius teams with Emerson on bioreactor control tech

by

Sartorius will integrate Emerson’s DeltaV distributed control system (DCS) into its Biostat STR range of bioreactor systems. The collaboration aims to address the challenge faced by life sciences companies in connecting process equipment to their plant’s automation system, which is complex and time-consuming. By integrating the Biostat STR Generation 3 range of bioreactors with the DeltaV DCS, the firms claim to be able to save commercial manufacturing sites up to 80% of their equipment integration time, enabling them to utilize…

August 7, 2023

Sustainability: Biomanufacturing challenges and potential solutions

by

Raw materials, manufacturing, and distribution all pose sustainability challenges for the biopharma industry, but to meet goals, organizations must work together to create meaningful changes, say experts. Environmental, social, and governance (ESG) documents are published and sent out across the newswires, but often sustainability-related statements are seen as box-ticking exercises or examples of “greenwashing.” However, when large pharmaceutical companies including GSK, AstraZeneca, and Roche launch a major sustainability program — calling on their network of suppliers to take action on…

August 7, 2023

GenScript expands RNA/DNA capacity on back of CGT demand

by

GenScript Biotech adds 400,000 square-feet of single RNA and non-viral DNA manufacturing capacity at its site in Zhenjiang, China to support biopharma cell and gene therapy (CGT) projects. The recently operational five-story 400,000 square-foot plant in Zhenjiang offers multiple segregated manufacturing and purification cleanrooms, Kay Huang, head of marketing at GenScript Biotech USA, said. “This new expansion will allow us to deliver GMP materials faster and help expedite our clients’ project timelines.” No financial details were divulged. “The demand come…

August 7, 2023